PPA
RARE icon

Parametric Portfolio Associates’s Ultragenyx Pharmaceutical RARE Stock Holding History

Parametric Portfolio Associates’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$3.11M Sell
42,776
-8,746
-17% -$609K ﹤0.01% 2162
2021
Q4 		$4.33M Sell
51,522
-1,402
-3% -$114K ﹤0.01% 1969
2021
Q3 		$4.77M Buy
52,924
+6,966
+15% +$630K ﹤0.01% 1861
2021
Q2 		$4.38M Sell
45,958
-37,904
-45% -$3.95M ﹤0.01% 1936
2021
Q1 		$9.55M Sell
83,862
-15,651
-16% -$2.13M 0.01% 1714
2020
Q4 		$13.8M Buy
99,513
+11,040
+12% +$1.31M 0.01% 1325
2020
Q3 		$7.27M Buy
88,473
+45,539
+106% +$3.77M 0.01% 1609
2020
Q2 		$3.36M Buy
42,934
+9,783
+30% +$648K ﹤0.01% 2154
2020
Q1 		$1.47M Buy
33,151
+4,818
+17% +$250K ﹤0.01% 2565
2019
Q4 		$1.21M Buy
28,333
+5,208
+23% +$215K ﹤0.01% 2962
2019
Q3 		$989K Buy
23,125
+3,119
+16% +$169K ﹤0.01% 3033
2019
Q2 		$1.27M Buy
20,006
+705
+4% +$44.9K ﹤0.01% 2929
2019
Q1 		$1.34M Buy
19,301
+3,557
+23% +$203K ﹤0.01% 2879
2018
Q4 		$685K Sell
15,744
-4,518
-22% -$247K ﹤0.01% 3165
2018
Q3 		$1.55M Buy
20,262
+1,208
+6% +$98.3K ﹤0.01% 2876
2018
Q2 		$1.47M Buy
19,054
+1,196
+7% +$77.2K ﹤0.01% 2861
2018
Q1 		$911K Sell
17,858
-4,217
-19% -$212K ﹤0.01% 3071
2017
Q4 		$1.02M Buy
22,075
+8,626
+64% +$423K ﹤0.01% 3011
2017
Q3 		$716K Sell
13,449
-439
-3% -$26K ﹤0.01% 3225
2017
Q2 		$863K Sell
13,888
-18,863
-58% -$1.14M ﹤0.01% 3060
2017
Q1 		$2.22M Buy
32,751
+8,353
+34% +$637K ﹤0.01% 2377
2016
Q4 		$1.72M Sell
24,398
-3,804
-13% -$270K ﹤0.01% 2478
2016
Q3 		$2M Buy
28,202
+5,421
+24% +$346K ﹤0.01% 2337
2016
Q2 		$1.11M Sell
22,781
-7,587
-25% -$491K ﹤0.01% 2738
2016
Q1 		$1.92M Buy
30,368
+21,191
+231% +$1.39M ﹤0.01% 2429
2015
Q4 		$1.03M Sell
9,177
-196
-2% -$19.6K ﹤0.01% 2747
2015
Q3 		$903K Buy
9,373
+1,210
+15% +$139K ﹤0.01% 2396
2015
Q2 		$836K Buy
8,163
+1,040
+15% +$80.8K ﹤0.01% 2926
2015
Q1 		$442K Buy
+7,123
New +$396K ﹤0.01% 3345

Other funds holding RARE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Parametric Portfolio Associates's RARE Position: Q1 2022 in Review

Parametric Portfolio Associates reduced its Ultragenyx Pharmaceutical (RARE) stake by 17% in Q1 2022, selling an estimated $609K and leaving 42,776 shares worth $3.11M. The position accounts for ﹤0.01% of the portfolio, ranked #2162.

Parametric Portfolio Associates first reported a position in RARE in Q1 2015 and has held it in 29 quarters since. The position peaked at $13.8M in Q4 2020. 240 funds tracked by Wall St. Rank hold RARE as of Q1 2022.

  • Parametric Portfolio Associates held 42,776 shares of Ultragenyx Pharmaceutical worth $3.11M as of Q1 2022.
  • Parametric Portfolio Associates sold 8,746 Ultragenyx Pharmaceutical shares in Q1 2022, an estimated $609K.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #2162 holding.
  • Parametric Portfolio Associates first reported a position in Ultragenyx Pharmaceutical in Q1 2015 and has held it in 29 quarters since.
  • Parametric Portfolio Associates's Ultragenyx Pharmaceutical position peaked at $13.8M in Q4 2020.
  • 240 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.